Question 1

After successful anxiety treatment, how likely is relapse and when should I worry?

Accepted Answer

Anxiety disorders are chronic relapsing conditions. After successful treatment, ~78% achieve remission, but nearly half of remitted individuals have residual sub-threshold symptoms *(Schopman 2021, ANZJP; PMID 33887978; ch01/lesson-05, Section 5.2)*. Recurrence rates climb: 2.1% at 1 year, 6.6% at 5 years, 10.6% at 10 years, 16.2% at 20 years *(Scholten 2021, Psychological Medicine; PMID 34294172; ch01/lesson-05, Section 5.2)*. Medication discontinuation carries an OR of 3.11 for relapse vs continued treatment *(Batelaan 2017, BMJ; PMID 28903922; ch04/lesson-07, Section 7.4)*. CBT shows superior durability (~14% relapse per Levy 2021, PMID 33915506 vs 36.4% post-medication discontinuation per Batelaan 2017, PMID 28903922). Guidelines recommend at least 12 months maintenance after remission. Residual insomnia is one of the strongest relapse predictors.

Question 2

How does treatment-induced remission compare: CBT vs SSRI?

Accepted Answer

Anxiety disorders are chronic relapsing conditions. After successful treatment, ~78% achieve remission, but nearly half of remitted individuals have residual sub-threshold symptoms *(Schopman 2021, ANZJP; PMID 33887978; ch01/lesson-05, Section 5.2)*. Recurrence rates climb: 2.1% at 1 year, 6.6% at 5 years, 10.6% at 10 years, 16.2% at 20 years *(Scholten 2021, Psychological Medicine; PMID 34294172; ch01/lesson-05, Section 5.2)*. Medication discontinuation carries an OR of 3.11 for relapse vs continued treatment *(Batelaan 2017, BMJ; PMID 28903922; ch04/lesson-07, Section 7.4)*. CBT shows superior durability (~14% relapse per Levy 2021, PMID 33915506 vs 36.4% post-medication discontinuation per Batelaan 2017, PMID 28903922). Guidelines recommend at least 12 months maintenance after remission. Residual insomnia is one of the strongest relapse predictors.

Question 3

What's the relapse rate if I stop medication?

Accepted Answer

Anxiety disorders are chronic relapsing conditions. After successful treatment, ~78% achieve remission, but nearly half of remitted individuals have residual sub-threshold symptoms *(Schopman 2021, ANZJP; PMID 33887978; ch01/lesson-05, Section 5.2)*. Recurrence rates climb: 2.1% at 1 year, 6.6% at 5 years, 10.6% at 10 years, 16.2% at 20 years *(Scholten 2021, Psychological Medicine; PMID 34294172; ch01/lesson-05, Section 5.2)*. Medication discontinuation carries an OR of 3.11 for relapse vs continued treatment *(Batelaan 2017, BMJ; PMID 28903922; ch04/lesson-07, Section 7.4)*. CBT shows superior durability (~14% relapse per Levy 2021, PMID 33915506 vs 36.4% post-medication discontinuation per Batelaan 2017, PMID 28903922). Guidelines recommend at least 12 months maintenance after remission. Residual insomnia is one of the strongest relapse predictors.

Question 4

How much residual impairment is normal even after successful treatment?

Accepted Answer

Anxiety disorders are chronic relapsing conditions. After successful treatment, ~78% achieve remission, but nearly half of remitted individuals have residual sub-threshold symptoms *(Schopman 2021, ANZJP; PMID 33887978; ch01/lesson-05, Section 5.2)*. Recurrence rates climb: 2.1% at 1 year, 6.6% at 5 years, 10.6% at 10 years, 16.2% at 20 years *(Scholten 2021, Psychological Medicine; PMID 34294172; ch01/lesson-05, Section 5.2)*. Medication discontinuation carries an OR of 3.11 for relapse vs continued treatment *(Batelaan 2017, BMJ; PMID 28903922; ch04/lesson-07, Section 7.4)*. CBT shows superior durability (~14% relapse per Levy 2021, PMID 33915506 vs 36.4% post-medication discontinuation per Batelaan 2017, PMID 28903922). Guidelines recommend at least 12 months maintenance after remission. Residual insomnia is one of the strongest relapse predictors.

Question 5

How long should maintenance treatment continue before attempting discontinuation?

Accepted Answer

Anxiety disorders are chronic relapsing conditions. After successful treatment, ~78% achieve remission, but nearly half of remitted individuals have residual sub-threshold symptoms *(Schopman 2021, ANZJP; PMID 33887978; ch01/lesson-05, Section 5.2)*. Recurrence rates climb: 2.1% at 1 year, 6.6% at 5 years, 10.6% at 10 years, 16.2% at 20 years *(Scholten 2021, Psychological Medicine; PMID 34294172; ch01/lesson-05, Section 5.2)*. Medication discontinuation carries an OR of 3.11 for relapse vs continued treatment *(Batelaan 2017, BMJ; PMID 28903922; ch04/lesson-07, Section 7.4)*. CBT shows superior durability (~14% relapse per Levy 2021, PMID 33915506 vs 36.4% post-medication discontinuation per Batelaan 2017, PMID 28903922). Guidelines recommend at least 12 months maintenance after remission. Residual insomnia is one of the strongest relapse predictors.

PsychHQ

Relapse Risk After Successful Anxiety Treatment: When to Worry and How Long to Maintain